Hormonal
Gut microbiota-derived lipopolysaccharides (LPS) and peptidoglycan (PGN) promote NAFLD progression by activating hepatic Toll-like receptors (TLR4, TLR2, NOD1/2), triggering inflammatory cytokine release and steatosis.
Your liver health is heavily influenced by what lives in your gut. An unhealthy diet can disrupt gut bacteria, allowing harmful bacterial parts (like LPS) to leak into your bloodstream and inflame your liver. Prioritizing a diet that supports a healthy gut microbiome (e.g., high fiber) may help reduce this inflammatory load on the liver.
The over-activated immune cells induced by the products generated from bacteria may result in more severe liver damage, inflammation, and fibrosis, thus accelerating the development of NAFLD.
Why this rating
The paper is a review summarizing multiple animal models and clinical associations; it does not present new primary clinical trial data.
Source
Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD)
Yun Ji et al. · Nutrients · 2019
DOI 10.3390/nu11081712
More from this paper
- Gut microbiota-derived metabolites, specifically Short-Chain Fatty Acids (SCFAs) like butyrate, acetate, and propionate, ameliorate NAFLD by inhibiting histone deacetylases (HDACs) and activating G-protein coupled receptors (GPR41, GPR43).Moderate
- Gut microbiota-derived Trimethylamine-N-oxide (TMAO) and secondary bile acids modulate NAFLD progression through regulation of bile acid metabolism, insulin resistance, and hepatic inflammation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →